Sildenafil for treatment of erectile dysfunction in men with diabetes

A randomized controlled trial

Marc S. Rendell, Jacob Rajfer, Pierre A. Wicker, Michael D. Smith

Research output: Contribution to journalArticle

532 Citations (Scopus)

Abstract

Context Erectile dysfunction is common in men with diabetes. Objective To assess the efficacy and safety of oral sildenafil citrate in the treatment of erectile dysfunction in men with diabetes. Design A multicenter, randomized, double-blind, placebo-controlled, flexible dose-escalation study conducted May through November 1996. Setting Patients' homes and 19 clinical practice centers in the United States. Patients A total of 268 men (mean age, 57 years) with erectile dysfunction (mean duration, 5.6 years) and diabetes (mean duration, 12 years). Interventions Patients were randomized to receive sildenafil (n = 136) or placebo (n = 132) as needed, but not more than once daily, for 12 weeks. Patients took the study drug or placebo 1 hour before anticipated sexual activity. The starting dose of sildenafil citrate was 50 mg, with the option to adjust the dose to 100 mg or 25 mg based on efficacy and tolerability, to be taken as needed. Main Outcome Measures Self-reported ability to achieve and maintain an erection for sexual intercourse according to the International Index of Erectile Function and adverse events. Results Two hundred fifty-two patients (94%) completed the study (131/136 in the sildenafil group, 121/132 in the placebo group). By intention-to-treat analysis, at 12 weeks, 74 (56%) of 131 patients in the sildenafil group reported improved erections compared with 13 (10%) of 127 patients in the placebo group (P

Original languageEnglish
Pages (from-to)421-426
Number of pages6
JournalJAMA - Journal of the American Medical Association
Volume281
Issue number5
DOIs
StatePublished - Feb 3 1999

Fingerprint

Erectile Dysfunction
Randomized Controlled Trials
Placebos
Therapeutics
Intention to Treat Analysis
Aptitude
Coitus
Sildenafil Citrate
Sexual Behavior
Outcome Assessment (Health Care)
Safety
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Sildenafil for treatment of erectile dysfunction in men with diabetes : A randomized controlled trial. / Rendell, Marc S.; Rajfer, Jacob; Wicker, Pierre A.; Smith, Michael D.

In: JAMA - Journal of the American Medical Association, Vol. 281, No. 5, 03.02.1999, p. 421-426.

Research output: Contribution to journalArticle

Rendell, Marc S. ; Rajfer, Jacob ; Wicker, Pierre A. ; Smith, Michael D. / Sildenafil for treatment of erectile dysfunction in men with diabetes : A randomized controlled trial. In: JAMA - Journal of the American Medical Association. 1999 ; Vol. 281, No. 5. pp. 421-426.
@article{48445f86410c47ee81dafa4b1c75fddd,
title = "Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial",
abstract = "Context Erectile dysfunction is common in men with diabetes. Objective To assess the efficacy and safety of oral sildenafil citrate in the treatment of erectile dysfunction in men with diabetes. Design A multicenter, randomized, double-blind, placebo-controlled, flexible dose-escalation study conducted May through November 1996. Setting Patients' homes and 19 clinical practice centers in the United States. Patients A total of 268 men (mean age, 57 years) with erectile dysfunction (mean duration, 5.6 years) and diabetes (mean duration, 12 years). Interventions Patients were randomized to receive sildenafil (n = 136) or placebo (n = 132) as needed, but not more than once daily, for 12 weeks. Patients took the study drug or placebo 1 hour before anticipated sexual activity. The starting dose of sildenafil citrate was 50 mg, with the option to adjust the dose to 100 mg or 25 mg based on efficacy and tolerability, to be taken as needed. Main Outcome Measures Self-reported ability to achieve and maintain an erection for sexual intercourse according to the International Index of Erectile Function and adverse events. Results Two hundred fifty-two patients (94{\%}) completed the study (131/136 in the sildenafil group, 121/132 in the placebo group). By intention-to-treat analysis, at 12 weeks, 74 (56{\%}) of 131 patients in the sildenafil group reported improved erections compared with 13 (10{\%}) of 127 patients in the placebo group (P",
author = "Rendell, {Marc S.} and Jacob Rajfer and Wicker, {Pierre A.} and Smith, {Michael D.}",
year = "1999",
month = "2",
day = "3",
doi = "10.1001/jama.281.5.421",
language = "English",
volume = "281",
pages = "421--426",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Sildenafil for treatment of erectile dysfunction in men with diabetes

T2 - A randomized controlled trial

AU - Rendell, Marc S.

AU - Rajfer, Jacob

AU - Wicker, Pierre A.

AU - Smith, Michael D.

PY - 1999/2/3

Y1 - 1999/2/3

N2 - Context Erectile dysfunction is common in men with diabetes. Objective To assess the efficacy and safety of oral sildenafil citrate in the treatment of erectile dysfunction in men with diabetes. Design A multicenter, randomized, double-blind, placebo-controlled, flexible dose-escalation study conducted May through November 1996. Setting Patients' homes and 19 clinical practice centers in the United States. Patients A total of 268 men (mean age, 57 years) with erectile dysfunction (mean duration, 5.6 years) and diabetes (mean duration, 12 years). Interventions Patients were randomized to receive sildenafil (n = 136) or placebo (n = 132) as needed, but not more than once daily, for 12 weeks. Patients took the study drug or placebo 1 hour before anticipated sexual activity. The starting dose of sildenafil citrate was 50 mg, with the option to adjust the dose to 100 mg or 25 mg based on efficacy and tolerability, to be taken as needed. Main Outcome Measures Self-reported ability to achieve and maintain an erection for sexual intercourse according to the International Index of Erectile Function and adverse events. Results Two hundred fifty-two patients (94%) completed the study (131/136 in the sildenafil group, 121/132 in the placebo group). By intention-to-treat analysis, at 12 weeks, 74 (56%) of 131 patients in the sildenafil group reported improved erections compared with 13 (10%) of 127 patients in the placebo group (P

AB - Context Erectile dysfunction is common in men with diabetes. Objective To assess the efficacy and safety of oral sildenafil citrate in the treatment of erectile dysfunction in men with diabetes. Design A multicenter, randomized, double-blind, placebo-controlled, flexible dose-escalation study conducted May through November 1996. Setting Patients' homes and 19 clinical practice centers in the United States. Patients A total of 268 men (mean age, 57 years) with erectile dysfunction (mean duration, 5.6 years) and diabetes (mean duration, 12 years). Interventions Patients were randomized to receive sildenafil (n = 136) or placebo (n = 132) as needed, but not more than once daily, for 12 weeks. Patients took the study drug or placebo 1 hour before anticipated sexual activity. The starting dose of sildenafil citrate was 50 mg, with the option to adjust the dose to 100 mg or 25 mg based on efficacy and tolerability, to be taken as needed. Main Outcome Measures Self-reported ability to achieve and maintain an erection for sexual intercourse according to the International Index of Erectile Function and adverse events. Results Two hundred fifty-two patients (94%) completed the study (131/136 in the sildenafil group, 121/132 in the placebo group). By intention-to-treat analysis, at 12 weeks, 74 (56%) of 131 patients in the sildenafil group reported improved erections compared with 13 (10%) of 127 patients in the placebo group (P

UR - http://www.scopus.com/inward/record.url?scp=0033518552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033518552&partnerID=8YFLogxK

U2 - 10.1001/jama.281.5.421

DO - 10.1001/jama.281.5.421

M3 - Article

VL - 281

SP - 421

EP - 426

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 5

ER -